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Objective. To establish whether supplementation with a standard oral dose of Beta-Galactosidase affects hydrogen breath excretion
in patients presenting with lactose malabsorption. Methods. Ninety-six consecutive patients positive to H2 Lactose Breath Test
were enrolled. Mean peak H2 levels, the time to reach the peak H2, the time to reach the cut-off value of 20 ppm, the cumulative
breath H2 excretion, the areas under the curve, and a Visual Analogical 10-point Scale for symptoms were calculated. Genotyping
of the C/T-13910 variant was carried out. Results. Following the oral administration of Beta-Galactosidase, in 21.88% of the cases,
H2 Lactose Breath Test became negative (Group A), while mean peak H2 levels (74.95 ppm versus 7.85), 𝑃 < 0.0000, in 17.71%
(Group B) were still positive, with the H2 level 20 ppm above the baseline, but the peak H2 levels were significantly lower than
those observed at the baseline test (186.7 ppm versus 66.64), 𝑃 < 0.0000, while in 60.41% (Group C) they were still positive with the
peak H2 levels similar to those observed at the baseline test (94.43 versus 81.60 ppm). All 96 individuals tested presented the C/C-
13910 genotype nonpersistence. Conclusions.The response to oral administration of Beta-Galactosidase in patients with symptoms
of lactose malabsorption presents a significant variability.
1. Introduction
Lactose malabsorption (LM), intolerance (LI) are a common
condition affecting a large proportion of the world’s pop-
ulation [1]. The most common cause of lactose intolerance
is lactase deficiency, a decreased production of the enzyme
lactase in the small intestinal villi. In normal conditions,
lactose is broken down in the small intestine, by lactase,
to glucose and galactose [2]. Lactase-deficient individuals
are not able to cleave this disaccharide and may become
symptomatic following the ingestion of lactose. In LM,
undigested lactose is fermented by the colonic flora causing,
inmany subjects, symptoms of LI such as diarrhoea, bloating,
nausea, borborygmi, and abdominal pain.
Several treatment approaches have been proposed over
the last few years [3], namely, addition of exogenous lac-
tase to intact milk [4, 5], low-lactose milk [6], yogurt,
and probiotics, due to their bacterial lactase activity [7–
9] and pharmacological and nonpharmacological strategies
that can prolong the contact time between enzyme and
substrate delaying gastrointestinal (GI) transit time [10] and
lactose administration for colonic adaptation [11]. Enzyme-
replacement treatment with microbial exogenous lactase
(obtained from yeasts or fungi) represents a possible strategy
for primary lactase deficiency. However, while several studies
have confirmed the efficacy of solid lactase preparations in
reducing both H2 excretion and symptoms [12, 13], other
comparative studies have shown that these preparations are
significantly less effective than prehydrolysed milk, probably
due to the gastric enzyme inactivation [14]. Since LI man-
agement with Beta-Galactosidase oral supplements remains
unclear and data regarding their efficacy in reducing the H2
breath concentration are inadequate, the aim of the present
investigation was to assess whether supplementation with
a standard oral dose of Beta-Galactosidase obtained from
Aspergillus oryzae affects hydrogen breath excretion and GI
symptoms in lactose intolerant patients.
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2. Materials and Methods
2.1. Patients. After approval of our Ethical Committee, we
have selected, between January 2011 and June 2011, 96 consec-
utive patients (80 females and 16males, overall mean age 38.0
years, range 18–65) who attended to the Gastroenterology
Outpatient Unit of University of Cagliari, Italy, for the pres-
ence of GI symptoms, abdominal pain, nausea, bloating, and
borborygmi, following lactose ingestion and were evaluated
for LM by means of H2 Lactose Breath Test (H2 LBT).
All patients were positive to H2 Lactose Breath Test and
were considered eligible for the study following a detailed
explanation regarding the investigation. All patients agreeing
to take part, following a detailed explanation regarding
the investigation, signed an informed consent form before
admission. Exclusion criteria were age <18 or >65 years,
diagnosis of neoplasia, inflammatory bowel disease, previous
GI surgery, history of allergy to milk proteins, lack of
compliance, history of liver, kidney, lung, heart, metabolic, or
neurological disorders, treatment with laxatives, antibiotics,
and prokinetics, or any other treatment known to affect the
colonic flora or motility in the month prior to the study.
Patients were interviewed regarding GI symptoms (abdom-
inal pain, nausea, bloating, and diarrhoea) and completed a
questionnaire, including items regarding demographic data
[e.g., sex, age, and body mass index (BMI)].
2.2. H2 Lactose Breath Test. The H2 LBT was performed
using a breath gas analyzer Model 12i MicroLyzer Plus
(Quintron Instruments, Milwaukee, WI, USA). Basal breath
specimens were obtained after overnight fasting; the day
before each breath test, the patients avoided eating slowly
absorbed carbohydrates (bread, pasta, or fibre) in order to
avoid delayed exhalation of hydrogen in the breath [15].
Cigarette and/or cigar smoking and physical exercise were
not permitted within the 12 hours before the test in order to
prevent hyperventilation and consequent changes in hydro-
gen content in the breath. Before starting the test, patients
rinsed their mouths with an antiseptic wash (Chlorhexidine
0.05% 20mL), followed by tap water, to avoid a rapid hydro-
gen peak due to the effect of oral bacteria on lactose. After
having evaluated the baseline H2 breath concentration, the
patients swallowed 25 gr of lactose (equivalent of the lactose
content in 500mLof cow’smilk) dissolved in 300mLofwater.
Over a 4-hour period, breath samples were collected at 30-
minute (min) intervals (from 8 a.m. till 12 noon) by having
the subjects exhale into a mylar foil gas two-bag system while
the patient was in a sitting position [16, 17]. The H2 LBT, in
agreement with the last International Guidelines (see, e.g.,
Rome Consensus Conference, 2007), was considered positive
for lactose malabsorption if the H2 concentration, in the
exhaled air, exceeded 20 parts per million (ppm) above the
baseline during themonitoring period [18, 19].Mean peakH2
levels (ppm), the time to peakH2 (min), and the time to reach
the cut-off value of 20 ppm were calculated [20, 21]. Also,
to better standardize data collection and further strengthen
the hypothesis of our study, we evaluated the cumulative
breath H2 excretion (ppm). We also assessed the value of
the areas under the entire curve (overall concentration of
exhaled H2 in 4 hours). Two H2 LBTs were carried out in
each patient, the initial test and the test following intervention
(15000Units of an acid-resistant Beta-Galactosidase obtained
fromAspergillus oryzae), andwere administered 1 hour before
lactose intake. As pointed out by themanufacturer, one tablet
(7500 Units) is able to hydrolyse 16 gr of lactose; thus, 2
tablets (equal to 15000Units) should be sufficient to hydrolyse
25 gr of lactose contained in the solution administered to
the patient. To avoid the effect of colonic acidification, the
mean time interval between the baseline test and following
the intervention was 8 days (range 9-10 days) [22].
2.3. Gastrointestinal Symptoms. On the day of the test, during
the 8 hours after substrate ingestion, all patients were asked
to rate four symptoms (abdominal pain, nausea, bloating, and
borborygmi) using a Visual Analogical 10-point Scale (VAS)
(0, no symptoms, to 10, the severity of the symptom). For each
patient, the VAS was calculated for each symptom as well as
the cumulative VAS by adding together the single symptom
VAS score of levels.
2.4. Genotyping. DNA was isolated from EDTA-blood using
a QiaAmp blood DNA Extraction kit (Qiagen, Hilden, Ger-
many). Briefly, 200 lL EDTA-blood was treated with protease
for 15min at 56∘C followed by addition of AL lysis buffer
and ethanol. The mixture was passed through a spin column
and washed according to the manufacturer’s instructions.
DNA was eluted with 100 l-LAE buffer and quantified on
agarose gel using lambda DNA as the standard. The DNA
fragment spanning C/T-13910 variants were amplified using
the forward primer [5#-GGATGCACTGCTGTGATGAG-
3#] and reverse primer [5#-CCC ACT GAC CTA TCC TCG
TG-3#] to also include positions.
Both sequencing and RFLP were carried out by using
this PCR product, which was done without knowledge of the
clinical data and the results of the LTT and LBT.
2.5. Sequencing. The PCR product was sequenced using an
automated DNA Sequencer (ABI3100 Applied Biosystems,
Ipswich, MA, USA) with the forward primer to read 400
base pairs (bps) in one direction. When necessary, the result
was reconfirmed by sequencing the other strand with the
reverse primer. All sequence data could be read with a
high confidence level from 213830 to 214190 bps (i.e., 361 bps
spanning the C/T13910 upstream of the LCT locus). MCM6
reference gene sequence (GenBank reference sequence) was
used because this SNP lies within the MCM6 locus, which is
the neighbouring from the gene upstream of the LCT locus.
2.6. Restriction Fragment Length Polymorphism. The PCR
product (300 ng)was digestedwith 1-2Units of BsmFI restric-
tion enzyme (New England Biolabs, Foster City, CA, USA)
and 1⋅reaction buffer B in a 30 lL reaction volume. The
reaction mixture was incubated at 65∘C for 4 hours and then
electrophoresed on a 2.5% agarose gel, stained with ethidium
bromide, and visualized under ultraviolet light (302 nm).
On the basis of the sequence information around the 13910
upstream position of the LCT locus, the expected band
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Figure 1
patternwas as follows: C/C variant: 342 and 106 bps (2 bands);
C/T variant: 342, 224, 118, and 106 bps (seen as 3 bands on the
gel as the 106 bps and 118 bps were not usually well resolved);
and the T/T variant: 224, 118, and 106 bps (seen as 2 bands,
for the same reason); the size of the uncut PCR product was
448 bps (one band).
2.7. Statistical Analysis. The statistics data were analysed
using SPSS software.We performed a test of normality on the
quantitative variables mean peakH2 levels (ppm), the time to
peak H2 (min), the time to reach the cut-off value of 20 ppm,
and the cumulative breath H2 excretion (ppm) to define the
type of test for the hypothesis testing. Tests of normality
were significant; therefore, we proceededwith nonparametric
tests for testing hypotheses about the variables mean peak
H2 levels (ppm), the time to peak H2 (min), the time to
reach the cut-off value of 20 ppm, the cumulative breath H2
excretion (ppm), and the areas under the curve. Scores of
abdominal pain, nausea, bloating and diarrhoea compared
before-after and were tested with the Kruskal-Wallis test. To
avoid spurious assessment of statistical significance between
groups differences, we proceeded to analyze the data with
ANOVA. In particular, we tested simultaneously Groups A,
B, and C before and after oral intake of Beta-Galactosidase
for the mean peak H2 levels (ppm), the time to peak H2
(min), the time to reach the cut-off value of 20 ppm, and the
cumulative breath H2 excretion (ppm).
3. Results
Following the oral administration of tilactase, in 21/96
(21.88%) H2 LBT became negative (Group A, Figure 1), while
mean peak H2 levels (74.95 versus 7.85 ppm) 𝑃 < 0.0000, in
17/96 (17.71% Group B, Figure 2) were still positive with H2
levels 20 ppm above the baseline but the mean peak H2 levels
were significantly lower than those observed at the baseline
test (186.7 versus 66.64 ppm) 𝑃 < 0.0000, while 58/96
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(60.41%GroupC, Figure 3) were still positivewithmean peak
H2 levels similar to those observed at the baseline test (81.60
versus 94.43 ppm). We also observed that the cumulative
values of breath H2 excretion (Figure 4) were significantly
reduced after Beta-Galactosidase administration in Group
A (5959 versus 593 ppm), 𝑃 < 0.0000, and in Group B
(11379 versus 5455), 𝑃 < 0.0005. There was no significant
reduction in Group C (24593 versus 21596 ppm) after Beta-
Galactosidase administration. At the baseline H2 LBT (after
ingestion only of lactose), in Group A, the mean peak H2
levels (Figure 5) were significantly lower than in B (74.95
versus 186.7 ppm), 𝑃 = 0.0006; furthermore, the time to
reach the cut-off value of 20 ppm (Figure 6) was significantly
longer in Group A than that observed in Group B (141.42
versus 100.58min), 𝑃 = 0.02, and Group C (141.42 versus
115.34min), 𝑃 = 0.03, and the time to reach the peak H2
levels (Figure 7)was significantly longer inA than inB (205.71
versus 153.75min), 𝑃 = 0.001, and Group C (205.71 versus
183.10min), 𝑃 = 0.002. No statistically significant result was
achieved by the analysis of the areas under the entire curve
before and after Beta-Galactosidase administration.
All 96 individuals tested presented the C/C-13910 geno-
type,which is the polymorphism for the Sardinian population
associated with lactase nonpersistence [23].
3.1. Effect of Tilactase on Symptoms. Following the oral
tilactase consumption, a significant reduction in the mean
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Table 1: Visual analogical scale for symptoms.
Abdominal pain Bloating Nausea Diarrhoea
Group A
Before Beta-Galactosidase 2.54 5.02 1.62 0.88
After Beta-Galactosidase 2.07 3.42∗ 1.09 0.28
∗
𝑃 = 0.02
Group B
Before Beta-Galactosidase 3.61 5.29 0.73 1.53
After Beta-Galactosidase 3.50 5.11 0.14∗ 0.53∗
∗
𝑃 = 0.04
∗
𝑃 = 0.02
Group C
Before Beta-Galactosidase 3.68 5.35 1.55 1.74
After Beta-Galactosidase 2.78∗ 4.47∗ 1.13 1.00∗
∗
𝑃 = 0.01
∗
𝑃 = 0.02
∗
𝑃 = 0.003
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clinical scores for abdominal pain, bloating, and diarrhoea
was observed in Group C; in Group B, a significant reduction
in the mean clinical score resulted in nausea and diarrhoea,
while in Group A a significant reduction in the mean clinical
score resulted in bloating (Table 1).
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4. Discussion
Results of the present study indicate that oral administration
of 15000 Units (600 Units × gr lactose) of Beta-Galactosidase
obtained from fermentation ofAspergillus oryzae, followed by
ingestion of a water lactose solution, in lactose malabsorber
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individuals, with genetically related hypolactasia with the
C/T-13910 variant and GI symptoms of LI, is effective in sig-
nificantly decreasing the mean peak H2 levels and the cumu-
lative values of breath H2 excretion in approximately 40% of
subjects (Groups A and B), while, in 60% of subjects (Group
C), the breath H2 excretion levels do not change with respect
to the baseline test. The value of the areas under the entire
curve could play a predictive role regarding the test response
after administration of lactase in order to understand how
a greater or lesser concentration of global H2 breath could
affect the outcome of the test in relation to the amount
of lactase administered. However, no significant result was
observed after statistical analysis. Regarding the effect of
tilactase ingestion on GI symptoms, a significant reduction
in the symptom score with the exception of nausea was
observed. It is noteworthy that these data indicate a signifi-
cant variability in the responses to oral Beta-Galactosidase.
Our study, in agreement with other works, has shown that
there is no direct correlation between symptoms and H2
breath excretion. We also observed that the clinical response
after administration of a standard dose of lactase does not
correlate directly with the H2 concentration in exhaled air.
This fact is particularly evident in Group C in which, after
taking lactase, any substantial change is not observed with
regard to the mean peak H2 levels and the cumulative breath
H2 excretion values. Also, though interesting, unfortunately,
our work did not take into account body weight and BMI
value of patients; in fact, many studies have been conducted
with the aim of evaluating the relationship between body
weight and the dose required for a positive effect of tilactase.
A possible explanation for the interindividual differences
could be the effect of variations in the degree of lactose
digestion (LD) [24], of the potential gastric inactivation of
the enzyme [25], of the intestinal motility patterns [26],
or of the gastric emptying [27]. At the baseline test, some
significant differences between the groups were present; for
instance, in Group A, we detected a longer time to reach
the cut-off value of 20 ppm and the time to reach the peak
H2 levels. In Group A, a delay in the orocecal transit time
could possibly be a possible explanation for the longer time
to reach the cut-off value as well as the time to reach the peak
H2 levels. A delay in the small intestine transit time suggests
that longer exposure between the Beta-Galactosidase and the
lactose in the intestinal lumen could contribute to improve
the LD [28–31]. Furthermore, the decrease in intestinal transit
time, prolonging the action of the Beta-Galactosidase in the
intestinal lumen, decreases, in turn, the osmotic load of the
lactose which, as a nonabsorbable sugar, could accelerate
the intestinal transit time reducing the time available for
lactose hydrolysis [30–32]. However, the transit time is not
the only explanation behind the different responses obtained
in the three groups after taking lactase. As discussed, other
mechanisms, not better known and currently unconvincing,
could play a role.
In Group B, following Beta-Galactosidase, the H2 LBT
was still positive, with H2 levels 20 ppm above baseline, and
the peak H2 levels and the cumulative breath H2 excretion
were, however, significantly lower than those observed at
the baseline H2 LBT. Of note in this group is the fact that,
at baseline H2 LBT, the mean peak levels of H2 were signifi-
cantly higher than those at Groups A andC. In this group, the
significant but partial response to Beta-Galactosidase could
be due to a lower concentration of the epithelial enzyme,
and therefore higher levels of exhaled H2 could be achieved
by the larger amount of lactose reaching the colonic lumen
where it is fermented by the flora in the colon. In these
hypotheses, a higher dose of oral Beta-Galactosidase could be
a useful tool for increasing the hydrolysis of ingested lactose
in the small bowel, thus reducing the amount of undigested
lactose reaching the large intestine. However, the high levels
of exhaled H2, observed in Group B, could also be the result
of the colonic bacteria Beta-Galactosidase activity or the
amount of methanogenic bacteria present in the colon. The
hydrogen produced following lactose ingestion, by lactose-
intolerant patients, is likely, at different rates, oxidised by
methanogenic bacteria; therefore, it could be argued that,
in Group B, nonsignificant amounts of H2 are consumed
by methanogenic and/or sulphate-reducing bacteria. There-
fore, an interindividual variability in the microbiota and in
the colonic bacteria Beta-Galactosidase activity is possibly
involved in determining the difference in the amount ofH2 in
the lactose colonic fermentation. For these reasons, in some
cases, an oral supplementation of oral lactase (over 15000
Units) could reduce the concentration of H2 expired in no
responder patients (GroupC) ormodify the severity of symp-
toms in Groups A and C. In approximately 60% of patients
(Group C), the oral administration of Beta-Galactosidase
was not effective in decreasing breath H2 excretion. The
“resistance” to the oral Beta-Galactosidase observed in these
patients could be the result of inactivation of the exogenous
enzyme.The Beta-Galactosidase, in order to effectivelymain-
tain the enzymatic activity in the conditions usually found
in the gastrointestinal tract such as gastric acidity and bile
concentrations, requires the mechanical protection of the
enzyme during the gastric passage and against the action
of the bile [33]. It has been demonstrated that gastric acid
reduces bacterial lactase activity in 20–60min [34]. If the
mechanical protection of the enzyme is disgregated in the
gastric lumen, the acid pH could reduce the action of the
residual Beta-Galactosidase. Gastric emptying and intestinal
transit should also be taken into consideration; a fast gastric
emptying and intestinal transit time with consequently a
shorter contact time between enzyme and substrate could
reduce the carbohydrate absorption. Studies that evaluated
the effect of propantheline and metoclopramide on lactose
digestion revealed that propantheline-induced prolongation
of gastric emptying improves lactose tolerance as measured
by breath H2 concentration compared to metoclopramide
[35]. It has already been hypothesized that the levels of breath
H2 excretion might influence the occurrence of symptoms
following lactose ingestion [36, 37].
In this respect, in the present series, the decrease in H2
levels in the breath does not seem to affect the symptom
scores; in fact, no significant positive correlation was found
between the peak H2 levels and the total symptom score, in
particular for abdominal pain and nausea.
Thepresent data are in agreementwith those by di Stefano
et al. [38] who found no correlation between the severity of
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symptoms and the level of breath H2 excretion. The causes
of the GI symptoms in lactose intolerant patients are not
clearly understood. Several factors could contribute to the
development of symptoms, for instance, psychological factors
[39], functional GI disorders, visceral sensitivity, or bowel
motor abnormalities [40]. This would appear to suggest that,
in addition to the digestion of lactose in the small intestine,
other factors may influence the onset of lactose intolerance
symptoms. Recently, the involvement of colonic factors has
been hypothesized [41–44]. The balance between the ability
of the colonic microbiota to ferment lactose and the ability
of the colon to remove the fermentation metabolites would
influence the onset of lactose intolerance, making it either
more severe or less severe. A low lactose fermenting capacity
of the colonic microbiota, which leads to inefficient removal
of maldigested lactose (and/or its intermediate fermentation
metabolites, e.g., glucose and galactose) or to a low absorp-
tion capacity of the colon or a low SCFA/gas-metabolizing
capacity of the colonic microbiota which leads to poor
removal of fermentation metabolites, may contribute to the
development of symptoms. Although, following oral Beta-
Galactosidase administration, an improvement in some GI
symptoms, bloating in Group A and nausea and diarrhoea in
Group B, was obtained, our findings show that, particularly in
patients not presenting a decrease in the H2 levels following
oral Beta-Galactosidase administration (Group C), a more
extensive improvement in abdominal symptoms (abdominal
pain, bloating, and diarrhoea) was observed. At the moment,
we have no security if the improvement in the severity of
symptoms observed inGroupC is the result of a placebo effect
or differentmetabolic response to lactase.Our results indicate
that oral administration of 15000 Units of Beta-Galactosidase
in lactose malabsorber individuals is effective in decreasing
significantly the mean peak H2 levels and the cumulative
values of breath H2 excretion in a small group of patients.
However, this reduction may not be directly correlated with
the severity of symptoms. It is plausible, therefore, that other
factors play an important role in the proper metabolism of
tilactase and the real benefits of the same after oral intake.
Further studies are needed to elicit the different impact of
oral administration of Beta-Galactosidase on GI symptoms
and on breath excretion of H2.
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